• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Loss of the H-2.33 private specificity by 3LL tumor cells correlates with the tumor potential to metastasize across the H-2K region genetic barriers.

作者信息

Isakov N, Feldman M, Segal S

机构信息

Department of Cell Biology, Weizmann Institute of Science, Rehovot.

出版信息

Exp Clin Immunogenet. 1984;1(3):170-4.

PMID:6401004
Abstract

Grafts of the metastatic 3LL Lewis lung carcinoma result in pulmonary metastases in mouse strains which share with the tumor strain of origin (C57BL/6, H-2b) the non-H-2 background genes and the H-2D/H-2L region of the major histocompatibility complex. Lung metastases across H-2K region disparities correlated with low expression of H-2Kb-encoded molecule on the tumor cell surface. We tested whether the 3LL tumor cells lack H-2Kb private and/or public specificities by staining 3LL tumor cells and spleen cells of different recombinant mouse strains with H-2d anti-H-2b and anti-3LL antisera, respectively, following absorption of the antisera on spleen cells from various recombinant mouse strains. The data demonstrated weak expression of H-2Kb public specificities (which could represent H-2Db/H-2Kb biregional encoded molecules) and a complete lack of expression of the H-2.33 H-2Kb private specificity by 3LL tumor cells. The findings provide a possible explanation for the 3LL metastatic potential across H-2Kb region disparities.

摘要

相似文献

1
Loss of the H-2.33 private specificity by 3LL tumor cells correlates with the tumor potential to metastasize across the H-2K region genetic barriers.
Exp Clin Immunogenet. 1984;1(3):170-4.
2
Loss of expression of transplantation antigens encoded by the H-2K locus on Lewis lung carcinoma cells and its relevance to the tumor's metastatic properties.
J Natl Cancer Inst. 1983 Jul;71(1):139-45.
3
An immune response against the alloantigens of the 3LL Lewis lung carcinoma prevents the growth of lung metastases, but not of local allografts.针对3LL Lewis肺癌同种异体抗原的免疫反应可阻止肺转移瘤的生长,但不能阻止局部同种异体移植物的生长。
Invasion Metastasis. 1982;2(1):12-32.
4
Control of progression of local tumor and pulmonary metastasis of the 3LL Lewis lung carcinoma by different histocompatibility requirements in mice.通过小鼠不同组织相容性要求控制3LL Lewis肺癌局部肿瘤进展和肺转移
J Natl Cancer Inst. 1981 May;66(5):919-26.
5
Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells.两种H-2K基因(同基因和异基因)的表达作为增强肿瘤细胞免疫识别的一种策略。
Gene Ther. 1995 Dec;2(10):757-65.
6
Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice.肿瘤抗原的表达与小鼠Lewis肺癌和B16黑色素瘤克隆的转移潜能相关。
Cancer Res. 1986 Nov;46(11):5772-8.
7
Abolishment of metastasis formation by murine tumor cells transfected with "foreign" H-2K genes.用“外源”H-2K基因转染的小鼠肿瘤细胞转移形成的消除。
Cancer Res. 1989 May 1;49(9):2366-73.
8
Genetic regulation of metastasis progression: the development of pulmonary metastases of the 3LL lung carcinoma is controlled by both a non-H-2 gene(s) and a gene(s) linked to the H-2D region of the mouse MHC.
Transplant Proc. 1981 Mar;13(1 Pt 2):778-82.
9
Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld).通过转染同种异体I类主要组织相容性复合体基因(H-2Ld)对小鼠肺癌(3LL)进行异种化。
Cancer Res. 1987 Jun 15;47(12):3136-40.
10
MHC antigens expressed on 3LL metastatic variants: correlation with the expression of a TSP-180 protein.
Adv Exp Med Biol. 1988;233:141-50. doi: 10.1007/978-1-4899-5037-6_16.

引用本文的文献

1
A Small β-Carboline Derivative "B-9-3" Modulates TGF-β Signaling Pathway Causing Tumor Regression .一种小β-咔啉衍生物“B-9-3”调节TGF-β信号通路导致肿瘤消退。
Front Pharmacol. 2018 Jul 19;9:788. doi: 10.3389/fphar.2018.00788. eCollection 2018.